Candel Therapeutics, Inc. (CADL)

Over the past six months, Candel Therapeutics, Inc. (CADL) stock has been influenced by several analyst actions and company developments. In October 2025, Stephens & Co. initiated coverage with an "Overweight" rating and a $15.00 price target, while LifeSci Capital initiated coverage with an "Outperform" rating and a $16.00 price target; Weiss Ratings reaffirmed a "Sell (D-)" rating. In September 2025, HC Wainwright & Co. reiterated a "Buy" rating with a $23.00 price target, but Bank of America downgraded CADL to a "Neutral" rating, lowering its price target from $13.00 to $7.00. In August 2025, the company reported Q2 2025 earnings of -$0.09 USD per share, exceeding analysts' estimates. In July 2025, Brookline Capital Management raised Candel Therapeutics to a "Strong-Buy" rating. In June 2025, HC Wainwright & Co. assumed coverage with a "Buy" rating and a $23.00 price target, and Candel Therapeutics announced positive results from its Phase 2 clinical trial for CAN-2409 in pancreatic cancer. In May 2025, the company released its Q1 2025 earnings report. In April 2025, Candel Therapeutics entered into a $130 million term loan facility with Trinity Capital Inc. and announced positive interim data for CAN-3110 in recurrent glioblastoma. In February 2025, B of A Securities initiated coverage with a "Buy" recommendation. The stock's 52-week high was $14.60 and its 52-week low was $3.79.

As a clinical-stage biopharmaceutical company, Candel Therapeutics, Inc. currently does not generate revenue from product sales, and therefore, there is no established demand seasonality for its products and services at this stage. The company's market position and future outlook are contingent on the successful clinical development and commercialization of its product candidates.

Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients within the Healthcare sector and Biotechnology industry. The company creates off-the-shelf oncolytic viral immunotherapies to stimulate a patient's immune system to fight cancer. Its major product candidates include CAN-2409, in Phase III trials for prostate cancer and Phase II trials for pancreatic and non-small cell lung cancer, and CAN-3110, in Phase Ib trials for recurrent high-grade glioma. The enLIGHTEN Discovery Platform is used to create new viral immunotherapy candidates for solid tumors. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Candel Therapeutics, Inc. is headquartered in Needham, Massachusetts, United States, and conducts clinical trials across multiple sites in North America and Europe.

Candel Therapeutics' brand reputation over the past year has been positively influenced by positive clinical trial data for CAN-3110 and CAN-2409, analyst endorsements with "Buy" and "Outperform" ratings, the appointment of Bali Pulendran, Ph.D., to its Research Advisory Board, and securing a $130 million term loan facility. While there have been some downgrades to "Neutral" by certain analysts, the overall sentiment from recent analyst coverage and clinical developments appears to be positive.

Candel Therapeutics, Inc. (US:CADL) has 176 institutional owners and shareholders, holding a total of 25,520,833 shares. Major institutional shareholders include Fmr Llc, FBIOX - Biotechnology Portfolio, Acorn Capital Advisors, Llc, BlackRock, Inc., Vanguard Group Inc, Portolan Capital Management, LLC, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Halter Ferguson Financial Inc.